Cite

HARVARD Citation

    Shafique, M. et al. (2019). A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer. Oncologist. pp. 887-e416. [Online]. 
  
Back to record